Here we have presented the phoenix rising pathway as a potential driver of compensatory proliferation, and advocated that the ability of COX-2 inhibitors to selectively inhibit the proliferation of tumour cells during therapy should be evaluated. This evidence concerns the gene PTGS2 and neoplasm.